HomeLAB • NASDAQ
add
Standard Biotools Inc
Previous close
$2.58
Day range
$2.54 - $2.66
Year range
$1.57 - $3.16
Market cap
960.13M USD
Avg Volume
2.73M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 45.54M | 81.30% |
Operating expense | 46.94M | 112.53% |
Net income | -32.16M | -90.92% |
Net profit margin | -70.61 | -5.31% |
Earnings per share | -0.24 | — |
EBITDA | -33.54M | -118.17% |
Effective tax rate | -0.40% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 462.28M | 199.14% |
Total assets | 777.67M | 109.24% |
Total liabilities | 200.35M | 27.16% |
Total equity | 577.32M | — |
Shares outstanding | 294.12M | — |
Price to book | 1.32 | — |
Return on assets | -17.59% | — |
Return on capital | -20.81% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -32.16M | -90.92% |
Cash from operations | -62.48M | -636.31% |
Cash from investing | 318.08M | 637.07% |
Cash from financing | -19.73M | -671.42% |
Net change in cash | 235.84M | 633.94% |
Free cash flow | -34.20M | -972.18% |
About
Standard BioTools Inc., previously known as Fluidigm Corp., offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits, and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.
Standard BioTools sells products to academic research institutions; translational research and medical centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology and plant and animal research companies; and contract research organizations. Wikipedia
Founded
1999
Headquarters
Website
Employees
537
